GLP-1 Medicaid Coverage by State

Updated April 20, 2026

Medicaid coverage of GLP-1 medications in 2026 is a patchwork. All 50 states plus DC cover GLP-1s for Type 2 diabetes. Only 13 states plus DC cover them for chronic weight management. The rest either explicitly exclude weight-loss indications or restrict coverage so tightly that practical access is nearly impossible.

If you're on Medicaid, your coverage depends entirely on your diagnosis and your state. This guide walks through where coverage exists, where it doesn't, what changed in 2026, and what to do if your state won't pay.

The National Picture: Diabetes Yes, Weight Loss Often No

Every state Medicaid program covers Ozempic and Mounjaro when prescribed for Type 2 diabetes. Most also cover them for cardiovascular risk reduction (an FDA-approved indication) and kidney disease. Coverage is usually subject to prior authorization and sometimes step therapy (trying cheaper drugs first), but approvals happen routinely.

Weight management is the fault line. Medicaid programs aren't required to cover weight-loss drugs, and most don't. The 13 states that do usually limit coverage with BMI thresholds (often BMI ≥ 30 or ≥ 27 with comorbidities), prior authorization, and step therapy.

States That Cover GLP-1s for Weight Loss (April 2026)

The 13 states with meaningful Medicaid coverage for weight management GLP-1s (Wegovy and Zepbound):

• Delaware — Cut coverage January 2026; eligibility now limited to diabetes-adjacent use. Despite the January cut, transitional coverage exists for patients already on therapy.
• Kansas
• Michigan — Coverage exists but is very restrictive; requires multiple prior auth denials of cheaper alternatives.
• Minnesota
• Mississippi
• Pennsylvania
• Rhode Island
• Virginia
• Wisconsin
• District of Columbia
• Massachusetts — "Limited" coverage; Zepbound preferred over Wegovy.
• New Jersey
• Connecticut
• New Mexico

Recent Changes: California and Delaware Cut Coverage

In January 2026, California and Delaware reduced or eliminated Medicaid coverage of GLP-1s for weight management, citing budget pressures. California Medi-Cal had briefly added weight-loss coverage in 2024 and quietly reversed the decision 18 months later. Delaware narrowed its criteria to effectively exclude most new applicants.

This is the reality of state Medicaid coverage: it moves with state budgets, not medical evidence. Coverage added in one budget cycle can be gone in the next.

States That Don't Cover Weight-Loss GLP-1s

The remaining 37+ states do not cover Wegovy or Zepbound through Medicaid for weight management. This includes large states like Texas, Florida, New York, Illinois, Georgia, North Carolina, and Ohio. Coverage in these states is limited to:

• Ozempic or Mounjaro for Type 2 diabetes
• Ozempic for cardiovascular risk
• Mounjaro or Zepbound for obstructive sleep apnea (newer indication, spotty coverage)

If you live in one of these states and need a GLP-1 for weight loss, Medicaid will say no. Prior authorization requests get denied. Step therapy gets invoked. The practical answer is to look beyond Medicaid.

The CMS BALANCE Model: May 2026 and Beyond

The CMS BALANCE Model launches May 1, 2026, and represents the first federal-level effort to expand Medicaid GLP-1 coverage. BALANCE is a voluntary state-opt-in program that provides federal matching funds for states to cover GLP-1s for weight management. States that opt in get significant cost-sharing with CMS, which addresses the budget concern that drove California and Delaware to cut.

Early expected participants: several mid-Atlantic and Midwest states. This will meaningfully expand the coverage map over 2026 and 2027. If your state isn't currently covered, check back — BALANCE enrollment is actively moving.

What to Do If Your State Doesn't Cover Weight-Loss GLP-1s

Check for a diabetes-adjacent diagnosis

If you have prediabetes, cardiovascular risk factors, or sleep apnea in addition to weight concerns, your doctor may be able to prescribe Ozempic or Mounjaro under a covered diagnosis. This is clinically legitimate — these drugs work for all these conditions — and it's the single most common path to Medicaid-covered GLP-1 access.

Self-pay via TrumpRx

TrumpRx cash pricing is the fallback for anyone whose Medicaid won't cover GLP-1s for weight loss:

• Wegovy pill: $149/month
• Wegovy injection: $199/month
• Zepbound: $299/month
• Ozempic: $199–$350/month

Manufacturer savings cards do not work with Medicaid (they're blocked by federal anti-kickback rules). So while you're on Medicaid, your only non-covered path is cash self-pay.

Patient Assistance Programs

NovoCare (Wegovy) and Lilly Cares (Zepbound) both accept Medicaid beneficiaries who meet income thresholds. Income limits are roughly 400% of the federal poverty level, which means most Medicaid enrollees qualify by definition. The application takes 4–8 weeks but can provide the drug at no cost if you're approved.

Medical Necessity Appeals

If Medicaid denies your GLP-1 prescription, you can appeal. Appeal success rates for GLP-1s are roughly 40–60% when supported by documentation of failed alternative therapies, BMI above 30 with comorbidities, or both. Your prescriber's office typically handles the appeal paperwork.

Prior Authorization: What to Expect

Even in covered states, prior authorization is required. Documentation that improves approval odds:

• BMI measurement (usually need ≥ 30, or ≥ 27 with comorbidity)
• Evidence of failed lifestyle intervention
• Other relevant diagnoses (prediabetes, sleep apnea, hypertension)
• Contraindication to cheaper alternatives

Processing typically takes 1–3 weeks. Denials can be appealed.

Bottom Line

• All 50 states cover GLP-1s for diabetes. If your diagnosis qualifies, Medicaid works.
• 13 states plus DC cover for weight loss. The rest don't, and some recently cut coverage.
• CMS BALANCE Model is expected to expand coverage through 2026–2027.
• TrumpRx is the practical self-pay bridge if your state won't cover you.
• Patient assistance programs provide free medication for income-qualified patients, including most Medicaid enrollees.